Roth Affirms Celldex (CLDX) at 'Focus Pick'; Solidifying Itself as Premier Cancer Immunotherapy Company
Tweet Send to a Friend
Roth Capital affirms Celldex (Nasdaq: CLDX) at Buy/Focus Pick with a price target of $43 following news that the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
